Study guide

14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT)

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT)

Key Takeaways Explain This Topic AI

Natural menopause is defined clinically as 12 consecutive months of spontaneous amenorrhea without other physiological or pathological etiology (average age 51.4 years); laboratory measurement of FSH or estradiol is not routinely required in healthy women >45 presenting with classic vasomotor and menstrual changes.

Under the Menopause Society 'Timing Hypothesis,' Menopausal Hormone Therapy (MHT) exhibits an optimal benefit-risk profile when initiated in symptomatic women <60 years of age or within 10 years of menopause onset, reducing all-cause mortality, coronary heart disease, and osteoporotic fractures.

The mandatory structural rule of systemic MHT states that women with an intact uterus MUST receive progestogen (or a SERM like bazedoxifene) combined with estrogen to prevent endometrial hyperplasia and adenocarcinoma; women with prior surgical hysterectomy receive estrogen alone.

Transdermal 17-beta estradiol bypasses hepatic first-pass metabolism, avoiding induction of prothrombotic coagulation factors, and is the preferred systemic route for women with hypertension, obesity, hypertriglyceridemia, or elevated baseline VTE risk.

Non-hormonal pharmacotherapy for vasomotor symptoms includes the first-in-class neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah 45 mg daily; requires baseline and periodic hepatic transaminase monitoring), low-dose paroxetine (7.5 mg daily; avoid in tamoxifen users due to CYP2D6 inhibition), venlafaxine, and gabapentin.

Last updated: August 2026

Perimenopause, Menopause & Hormone Replacement Therapy (HRT)

The menopausal transition represents a profound neuroendocrine and multisystem physiological evolution in women. Advanced practice nursing in adult-gerontology requires expertise in interpreting menstrual irregularities, managing debilitating vasomotor and genitourinary symptoms, assessing cardiovascular and skeletal risk profiles, and navigating the complexities of systemic versus local menopausal hormone therapy (MHT).

1. Reproductive Aging Taxonomy & Endocrinology

The Stages of Reproductive Aging Workshop (STRAW + 10) defines the staging criteria from peak reproductive life through late postmenopause. +---------------------------------------------------------------------------------------------------+

  • | STRAW + 10 REPRODUCTIVE AGING SPECTRUM |
  • | |
  • | [STAGE -2: EARLY MENOPAUSAL TRANSITION (PERIMENOPAUSE)] |
  • | - Menstrual Cycles: Variable cycle length; persistent difference of ≥7 days in length of |
  • | consecutive cycles. |
  • | - Endocrine: Declining inhibin B; fluctuating estradiol; variable/elevated early follicular FSH.|
  • | | |
  • | v |
  • | [STAGE -1: LATE MENOPAUSAL TRANSITION (PERIMENOPAUSE)] |
  • | - Menstrual Cycles: Marked cycle irregularity with interval of amenorrhea ≥60 days. |
  • | - Symptoms: Vasomotor symptoms (VMS) peak in prevalence and severity. |
  • | - Endocrine: Elevated FSH (>25 mIU/mL); erratic estradiol surges and troughs. |
  • | | |
  • | v |
  • | [STAGE 0: FINAL MENSTRUAL PERIOD (FMP) / NATURAL MENOPAUSE] |
  • | - Diagnostic Hallmark: 12 CONSECUTIVE MONTHS of spontaneous amenorrhea in a woman ≥45 years |
  • | without other pathological or physiological cause. (Median age in US: 51.4 years). |
  • | | |
  • | v |
  • | [STAGE +1 to +2: EARLY & LATE POSTMENOPAUSE] |
  • | - Endocrine: Depleted ovarian follicular reserve -> Permanent loss of negative feedback from |
  • | estradiol and inhibin B -> Persistently elevated FSH (typically >40 mIU/mL) and low estradiol.|
  • | - Clinical: Progressive urogenital atrophy (Genitourinary Syndrome of Menopause) and bone loss. |
  • +---------------------------------------------------------------------------------------------------+

Clinical Definitions:

Premature Ovarian Insufficiency (POI): Loss of normal ovarian function occurring before age 40 , characterized by amenorrhea ≥ 4 months \ge 4\text{ months} ≥ 4 months , hypoestrogenism, and elevated gonadotropins (two serum FSH levels > 40 IU/L >40\text{ IU/L} > 40 IU/L obtained ≥ 4 weeks \ge 4\text{ weeks} ≥ 4 weeks apart). Requires physiological MHT until at least the median age of natural menopause (~51 years) to preserve bone mineral density and reduce premature cardiovascular mortality.

Early Menopause: Menopause occurring between ages 40 and 45.

Diagnostic Lab Testing Rule: In women aged > 45 >45 > 45 years presenting with classic perimenopausal or menopausal symptoms (irregular menses, vasomotor flushes, vaginal dryness), routine FSH and estradiol testing is NOT recommended or required . In this cohort, FSH levels fluctuate unpredictably day-to-day and do not alter clinical management.

2. Pathophysiology of Clinical Manifestations +---------------------------------------------------------------------------------------------------+

  • | NEUROENDOCRINE PATHOPHYSIOLOGY OF VASOMOTOR FLUSHES |
  • | |
  • | [DECLINING OVARIAN ESTROGEN] |
  • | | |
  • | v |
  • | [LOSS OF NEGATIVE FEEDBACK ON ARCUATE NUCLEUS OF HYPOTHALAMUS] |
  • | - Hypertrophy and upregulation of KNDy neurons (expressing Kisspeptin, Neurokinin B, Dynorphin) |
  • | - Excessive release of Neurokinin B (NKB) |
  • | | |
  • | v |
  • | [ACTIVATION OF NEUROKININ-3 (NK3) RECEPTORS ON THERMOREGULATORY CENTER] |
  • | - Narrowing of the hypothalamic thermoregulatory set-point window |
  • | - Minor core body temperature elevations trigger exaggerated heat-dissipation responses: |
  • | * Profuse cutaneous vasodilation (flushing of face/chest) |
  • | * Intense diaphoresis and tachycardia followed by chills / shivering |
  • +---------------------------------------------------------------------------------------------------+
  • Genitourinary Syndrome of Menopause (GSM)

GSM encompasses anatomical, histological, and functional changes in the labia, clitoris, vagina, urethra, and bladder driven by estrogen depletion:

Pathophysiology: Loss of estrogen leads to thinning and desquamation of the stratified squamous epithelium of the vaginal mucosa, loss of vaginal rugae, diminished submucosal capillary vascularity, and loss of intracellular glycogen.

Microbiome Shift: Absence of glycogen causes depletion of protective Lactobacillus species. Vaginal pH \text{pH} pH rises from an acidic baseline ( 3.8 – 4.5 3.8\text{--}4.5 3.8 – 4.5 ) to alkaline ( > 5.0 – 6.5 >5.0\text{--}6.5 > 5.0 – 6.5 ) , predisposing to colonization by enteric pathogens ( E. coli , Enterococcus ).

Clinical Presentation: Vulvovaginal dryness, severe burning, pruritus, dyspareunia (painful intercourse), introital stenosis, postcoital spotting, urinary urgency, dysuria, and recurrent postmenopausal urinary tract infections (UTIs) .

Organ System Estrogen-Replete State Postmenopausal Estrogen-Depleted State Clinical Sequelae

Thermoregulatory Stable hypothalamic set-point Hypertrophied KNDy neurons / NKB release Hot flashes, night sweats, sleep fragmentation

Urogenital Thick rugated mucosa; pH 3.8–4.5; Lactobacillus dominant Pale, smooth, friable mucosa; pH >5.0; loss of Lactobacillus GSM: Dyspareunia, vaginal dryness, recurrent UTIs

Skeletal Estrogen promotes osteoclast apoptosis; suppresses RANKL Unrestrained RANKL -> Osteoclast overactivity Accelerated bone resorption (3–5% loss/year in early postmenopause)

Cardiovascular Favorable lipid profile (high HDL, low LDL); vasodilation Increased LDL, triglycerides, ApoB; decreased HDL; arterial stiffening Increased risk of atherosclerotic coronary artery disease

Metabolic / Body Comp Gynoid fat distribution (gluteofemoral) Android fat distribution (visceral adiposity); insulin resistance Metabolic syndrome, non-alcoholic fatty liver disease

  • 3. Menopausal Hormone Therapy (MHT / HRT)
  • The "Timing Hypothesis" / "Window of Opportunity"

Data from randomized trials (including extended follow-ups of the Women's Health Initiative [WHI]) and consensus guidelines from The Menopause Society (formerly NAMS 2022/2023) confirm that the safety and efficacy of MHT depend fundamentally on age and time since menopause onset : +---------------------------------------------------------------------------------------------------+

  • | THE MENOPAUSE SOCIETY: TIMING HYPOTHESIS |
  • | |
  • | [FAVORABLE BENEFIT-RISK PROFILE: INITIATION IN WINDOW OF OPPORTUNITY] |
  • | - Criteria: Age <60 years OR within 10 years of menopause onset. |
  • | - Clinical Benefits: |
  • | * Statistically significant reduction in all-cause mortality (RR ~0.70 - 0.80) |
  • | * Significant reduction in Coronary Heart Disease (CHD) and myocardial infarction |
  • | * Robust reduction in osteoporotic hip and vertebral fractures |
  • | * Complete resolution of moderate-to-severe vasomotor symptoms and sleep disturbance |
  • | |
  • | [UNFAVORABLE BENEFIT-RISK PROFILE: LATE INITIATION] |
  • | - Criteria: Age ≥60 years OR >10 - 20 years past menopause onset. |
  • | - Clinical Risks: Increased incidence of stroke, coronary events, VTE, and dementia. |
  • +---------------------------------------------------------------------------------------------------+

The Mandatory Structural Rule of Systemic MHT +---------------------------------------------------------------------------------------------------+

  • | SYSTEMIC MHT REGIMEN SELECTION RULES |
  • | |
  • | 1. INTACT UTERUS (No Prior Hysterectomy): |
  • | - MUST PRESCRIBE COMBINED ESTROGEN + PROGESTOGEN (or Estrogen + Bazedoxifene SERM). |
  • | - Mechanism: Unopposed systemic estrogen stimulates continuous endometrial mitotic activity, |
  • | increasing the risk of endometrial hyperplasia and adenocarcinoma 8- to 10-fold! |
  • | - Progestogen options: |
  • | * Micronized Progesterone (Prometrium): 100 mg daily continuous OR 200 mg cyclic 12-14 d/mo|
  • | * Medroxyprogesterone Acetate (MPA): 2.5 mg daily continuous OR 5 mg cyclic 12-14 d/mo |
  • | * Levonorgestrel 52 mg IUD (off-label endometrial protection for MHT) |
  • | |
  • | 2. ABSENT UTERUS (Prior Surgical Hysterectomy): |
  • | - PRESCRIBE ESTROGEN ALONE (ET - Estrogen Therapy). |
  • | - Clinical Rationale: No endometrial tissue exists; progestogen is NOT required. In the WHI, |
  • | estrogen-alone therapy showed no increase in breast cancer and a trend toward reduction. |
  • +---------------------------------------------------------------------------------------------------+

Routes of Administration: Transdermal vs. Oral Estrogen +---------------------------------------------------------------------------------------------------+

  • | TRANSDERMAL VS. ORAL 17-BETA ESTRADIOL |
  • | |
  • | TRANSDERMAL ESTRADIOL (Patch, Gel, Spray) ORAL ESTRADIOL (Pills) |
  • | - Bypasses hepatic first-pass metabolism. - Subject to hepatic first-pass metabolism. |
  • | - NO induction of hepatic coagulation factors - Induces synthesis of Factors II, VII, VIII, |
  • | (Factors VII, VIII, prothrombin). X, and fibrinogen; lowers Antithrombin III. |
  • | - Negligible/no increase in VTE or stroke risk. - Increases relative risk of VTE and Stroke. |
  • | - Neutral effect on serum triglycerides. - Increases serum triglycerides significantly. |
  • | - PREFERRED INITIAL ROUTE FOR: - Avoid in women with hypertriglyceridemia, |
  • | * Hypertension, Obesity (BMI ≥30 kg/m²) uncontrolled hypertension, or VTE risks. |
  • | * Hypertriglyceridemia, Diabetes mellitus |
  • | * Elevated baseline thromboembolic risk |
  • | * Gallbladder disease / cholelithiasis |
  • +---------------------------------------------------------------------------------------------------+
  • Local (Vaginal) Estrogen Therapy for GSM

Formulations: Vaginal estradiol cream (0.5–1 g 2–3 times/week), low-dose estradiol vaginal tablets (Vagifem 10 mcg twice weekly), or estradiol vaginal ring (Estring 7.5 mcg/24 hr replaced every 90 days).

Pharmacokinetics & Safety: Minimal systemic absorption. Re-acidifies vaginal pH \text{pH} pH , restores glycogen and Lactobacillus , thickens epithelium, and resolves dyspareunia and recurrent UTIs.

Critical Board Rule: Local low-dose vaginal estrogen DOES NOT REQUIRE co-administration of a progestogen , even in women with an intact uterus.

  • Absolute Contraindications to Systemic MHT
  • Current, past, or suspected Breast Cancer
  • Known or suspected Estrogen-dependent Neoplasia (e.g., Endometrial Adenocarcinoma)
  • Active or past history of Venous Thromboembolism (DVT or PE)
  • Active or past history of Arterial Thromboembolism (Ischemic Stroke, TIA, Myocardial Infarction)
  • Active severe Liver Disease / Hepatic Impairment (elevated baseline transaminases)
  • Unexplained, undiagnosed Abnormal Uterine Bleeding (AUB) (must rule out malignancy first!)
  • Known or suspected pregnancy; Porphyria cutanea tarda
  • 4. Non-Hormonal Pharmacotherapy for Vasomotor Symptoms

For patients with absolute contraindications to MHT (e.g., breast cancer survivors) or those who choose not to take hormones, evidence-based non-hormonal agents are available: +---------------------------------------------------------------------------------------------------+

  • | NON-HORMONAL PHARMACOTHERAPY FOR HOT FLASHES |
  • | |
  • | 1. NEUROKININ-3 (NK3) RECEPTOR ANTAGONIST: |
  • | - Fezolinetant (Veozah): 45 mg orally once daily with or without food. |
  • | - MOA: Selectively blocks NKB binding on KNDy neurons in the hypothalamus, directly restoring|
  • | thermoregulatory set-point balance. First non-hormonal agent targeting root pathophysiology|
  • | - Hepatic Safety Monitoring: MUST obtain baseline ALT, AST, total and direct bilirubin. |
  • | Repeat transaminases at 3 months, 6 months, and 9 months of therapy. |
  • | - Contraindications: Severe renal impairment (eGFR <30 mL/min), cirrhosis, or concomitant |
  • | use of moderate/strong CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). |
  • | |
  • | 2. SELECTIVE SEROTONIN / NOREPINEPHRINE REUPTAKE INHIBITORS (SSRIs / SNRIs): |
  • | - Paroxetine Mesylate (Brisdelle): 7.5 mg orally at bedtime. (Only FDA-approved SSRI for VMS)|
  • | * CRITICAL BOARD DRUG INTERACTION: NEVER prescribe paroxetine or fluoxetine to women taking|
  • | TAMOXIFEN! Paroxetine/fluoxetine are potent CYP2D6 inhibitors that block conversion of |
  • | tamoxifen into its active metabolite (endoxifen), causing breast cancer recurrence. |
  • | - Venlafaxine (Effexor XR): 37.5 to 75 mg orally daily. (First-line choice for women on |
  • | tamoxifen due to negligible CYP2D6 inhibition; monitor blood pressure). |
  • | - Desvenlafaxine (Pristiq): 100 mg daily; Escitalopram: 10 - 20 mg daily. |
  • | |
  • | 3. GABAPENTINOIDS: |
  • | - Gabapentin (Neurontin): 300 to 900 mg orally at bedtime. Excellent for nocturnal hot |
  • | flashes accompanied by significant sleep architecture disruption. (Sedation side effect). |
  • | |
  • | 4. CENTRALLY ACTING ALPHA-2 AGONISTS: |
  • | - Clonidine: 0.1 mg daily oral or weekly transdermal patch. (Side effects: dry mouth, |
  • | sedation, hypotension, rebound hypertension upon abrupt withdrawal). |
  • +---------------------------------------------------------------------------------------------------+
  • 5. Postmenopausal Osteoporosis Screening, FRAX & Management

Estrogen deficiency accelerates bone turnover, decoupling osteoclastic bone resorption from osteoblastic formation.

A. Screening Guidelines (USPSTF Grade B)

Universal Screening: All women aged ≥ 65 years \ge 65\text{ years} ≥ 65 years via Dual-Energy X-ray Absorptiometry (DEXA) of the lumbar spine and femoral neck/total hip.

Targeted Screening in Younger Postmenopausal Women (<65 years): Screen if 10-year major osteoporotic fracture risk on the FRAX tool is ≥ 8.4 % \ge 8.4\% ≥ 8.4% (equivalent to a 65-year-old white female without additional risk factors) OR if clinical risk factors are present (current smoking, low body weight < 127 lbs <127\text{ lbs} < 127 lbs [BMI < 21 kg/m 2 <21\text{ kg/m}^2 < 21 kg/m 2 ], parental hip fracture, glucocorticoid therapy ≥ 5 mg \ge 5\text{ mg} ≥ 5 mg prednisone equivalent daily ≥ 3 months \ge 3\text{ months} ≥ 3 months , rheumatoid arthritis, heavy alcohol use).

  • B. World Health Organization (WHO) T-Score Diagnostic Criteria
  • Normal: T-score ≥ − 1.0 \ge -1.0 ≥ − 1.0 standard deviations (SD)
  • Osteopenia (Low Bone Mass): T-score between − 1.0 -1.0 − 1.0 and − 2.5 -2.5 − 2.5 SD

Osteoporosis:

  • T-score ≤ − 2.5 \le -2.5 ≤ − 2.5 SD at lumbar spine, total hip, or femoral neck; OR
  • History of a Fragility (Low-Trauma) Fracture of the hip or spine, regardless of T-score; OR

Osteopenia (T-score − 1.0 -1.0 − 1.0 to − 2.5 -2.5 − 2.5 ) plus elevated FRAX 10-year probability of hip fracture ≥ 3.0 % \ge 3.0\% ≥ 3.0% or major osteoporotic fracture (MOF) ≥ 20 % \ge 20\% ≥ 20% .

C. Pharmacotherapy for Postmenopausal Osteoporosis

First-Line Antiresorptive Therapy (Oral Bisphosphonates):

Alendronate (Fosamax) 70 mg weekly or Risedronate (Actonel) 35 mg weekly.

Administration Protocol: Take first thing in the morning with a full 8-ounce glass of plain water, at least 30–60 minutes before any food, beverage, or other medications. Must remain upright (sitting or standing) for ≥ 30 minutes \ge 30\text{ minutes} ≥ 30 minutes to prevent pill-induced erosive esophagitis.

Contraindications: Esophageal stricture/achalasia, inability to sit upright for 30 minutes, severe renal impairment (eGFR < 35 mL/min <35\text{ mL/min} < 35 mL/min ).

Long-Term Adverse Events: Atypical subtrochanteric femur fractures and Osteonecrosis of the Jaw (ONJ). Consider a "drug holiday" after 3–5 years of treatment in low-to-moderate risk patients.

IV Bisphosphonate: Zoledronic Acid (Reclast) 5 mg IV infusion once yearly (eGFR must be ≥ 35 mL/min \ge 35\text{ mL/min} ≥ 35 mL/min ; ensure adequate hydration).

RANKL Inhibitor: Denosumab (Prolia) 60 mg SubQ every 6 months. Safe in renal impairment. Critical Pearl: Discontinuation causes rapid rebound bone loss and severe risk of multiple vertebral fractures; must transition immediately to a bisphosphonate if stopped.

SERM: Raloxifene (Evista) 60 mg daily. Estrogen agonist in bone (prevents vertebral fractures); estrogen antagonist in breast (reduces invasive ER-positive breast cancer risk) and uterus. Does not cause endometrial hyperplasia. Side effect: Worsens hot flashes and increases VTE risk.

Baseline Supplementation: Calcium 1 , 200 mg/day 1,200\text{ mg/day} 1 , 200 mg/day (dietary + supplement) and Vitamin D3 800 – 2 , 000 IU/day 800\text{--}2,000\text{ IU/day} 800 – 2 , 000 IU/day .

6. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+

  • | ANCC AGPCNP CLINICAL EXAM PEARLS |
  • | |
  • | - Any postmenopausal woman with an intact uterus who receives systemic estrogen MUST also |
  • | receive a progestogen to prevent endometrial cancer. (Estrogen alone = 8-10x cancer risk!). |
  • | |
  • | - In women with prior hysterectomy, prescribe Estrogen ALONE. Progestogens are not indicated. |
  • | |
  • | - Local vaginal estrogen for GSM does NOT require a progestogen, carries minimal systemic |
  • | absorption, and is first-line for postmenopausal dyspareunia and recurrent UTIs. |
  • | |
  • | - Paroxetine and Fluoxetine are strictly CONTRAINDICATED in patients taking TAMOXIFEN due to |
  • | potent CYP2D6 inhibition; use VENLAFAXINE (SNRI) instead. |
  • | |
  • | - Fezolinetant (Veozah) is an NK3 receptor antagonist for hot flashes that requires baseline, |
  • | 3-month, 6-month, and 9-month hepatic transaminase monitoring. |
  • | |
  • | - In a healthy 52-year-old female with classic hot flashes and amenorrhea, do NOT order FSH/LH; |
  • | diagnose menopause clinically. |
  • +---------------------------------------------------------------------------------------------------+